In early clinical trials, nabiximols has generally been well tolerated.<ref>{{cite journal |vauthors=Wade D, Makela P, Robson P, House H, Bateman C |title=Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients |journal=Mult Scler |volume=10 |issue=4 |pages=434–41 |year=2004 |pmid=15327042 |doi=10.1191/1352458504ms1082oa}}</ref><ref>{{cite journal |vauthors=Wade D, Makela P, House H, Bateman C, Robson P |title=Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis |journal=Mult Scler |volume=12 |issue=5 |pages=639–45 |year=2006 |pmid=17086911 |doi=10.1177/1352458505070618}}</ref><ref>{{cite journal |vauthors=Wade D, Robson P, House H, Makela P, Aram J |title=A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms |journal=Clin Rehabil |volume=17 |issue=1 |pages=21–9 |year=2003 |pmid=12617376 |doi=10.1191/0269215503cr581oa}}</ref> The most common adverse effects in Phase III trials were dizziness (25%), drowsiness (8%) and disorientation (4%); 12% of subjects stopped taking the drug because of the side effects. No investigations regarding the potential for [[Substance dependence|dependence]] are available, but such a potential is unlikely considering the pharmacological properties of the two components.<ref name="Schubert" />

 

